Inventor · disambiguated record
Angus Dalgleish
Also filed as: DALGLEISH ANGUS · DALGLEISH ANGUS G · DALGLEISH ANGUS GEORGE
23 granted patents·21 pending applications·169 citations·filing 1994–2024
94Inventor score
Top patents by PatentIndex Score
44 records- 0194US10758514B2Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumourGW PHARMA LTD·Filed 2018·Granted Sep 1, 2020·22 cites·7 claims
- 0293US11000486B2Combination of cannabinoids in the treatment of leukaemiaGW RES LTD·Filed 2018·Granted May 11, 2021·16 cites·18 claims
- 0389US12161607B2Combination of cannabinoids in the treatment of leukemiaJAZZ PHARMACEUTICALS RESEARCH UK LTD·Filed 2021·Granted Dec 10, 2024·2 cites·16 claims
- 0489US8715677B2Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapyBARTLETT JUSTIN B·Filed 2006·Granted May 6, 2014·48 cites·15 claims
- 0582US11351165B2Agent that increases the expression of the opioid kappa 1 for the treatment of cancerLDN PHARMA LTD·Filed 2018·Granted Jun 7, 2022·2 cites·15 claims
- 0682US2025032481A1Priming of cancer cells with low dose naltrexoneLDN PHARMA LTD·Filed 2024·Application pending·0 cites
- 0778US8097244B2Human prostate cell lines in cancer treatmentDALGLEISH ANGUS GEORGE·Filed 2008·Granted Jan 17, 2012·1 cites·11 claims
- 0877US11885796B2Assay to identify anti-cancer agentsLDN PHARMA LTD·Filed 2018·Granted Jan 30, 2024·1 cites·12 claims
- 0977US11304943B2Combination for use in the treatment of lung cancerLDN PHARMA LTD·Filed 2018·Granted Apr 19, 2022·1 cites·14 claims
- 1077US9895438B2Treatment of cancer with naltrexoneCANCER VACCINE INST·Filed 2014·Granted Feb 20, 2018·3 cites·4 claims
- 1176US2023390388A1Treatment of Cancer with NaltrexoneLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 1273US2023349885A1Assay to identify anti-cancer agentsLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 1372US12144807B2Priming of cancer cells with low dose naltrexoneCANCER VACCINE INST·Filed 2021·Granted Nov 19, 2024·0 cites·13 claims
- 1472US11065245B2Priming of cancer cells with low dose naltrexoneCANCER VACCINE INST·Filed 2015·Granted Jul 20, 2021·1 cites·13 claims
- 1571US2023381171A1Autoimmune therapyLDN PHARMA LTD·Filed 2023·Application pending·0 cites
- 1670US2022040295A1Treatment of Cancer With NaltrexoneLDN PHARMA LTD·Filed 2021·Application pending·0 cites
- 1768US7438922B2Human prostate cell lines in cancer treatmentONYVAX LTD·Filed 2004·Granted Oct 21, 2008·1 cites·14 claims
- 1867US12029737B2Autoimmune therapyLDN PHARMA LTD·Filed 2019·Granted Jul 9, 2024·0 cites·5 claims
- 1967US8841325B2Immunomodulatory compounds for the restoration of vitamin D sensitivity in vitamin D resistant tumor cellsBROSSEAU CAROLE·Filed 2010·Granted Sep 23, 2014·4 cites·15 claims
- 2065US6699483B1Cancer treatmentsONYVAX LTD·Filed 1999·Granted Mar 2, 2004·30 cites·24 claims
- 2162US8034360B2Use of human prostate cell lines in cancer treatmentONYVAX LTD·Filed 2005·Granted Oct 11, 2011·0 cites·13 claims
- 2260US8545835B2Human prostate cell lines in cancer treatmentDALGLEISH ANGUS GEORGE·Filed 2012·Granted Oct 1, 2013·0 cites·13 claims
- 2360US5935579AAIDS therapy and vaccineRETROSCREEN LTD·Filed 1994·Granted Aug 10, 1999·24 cites·9 claims
- 2460US2005019336A1Human prostate cell lines in cancer treatmentFiled 2003·Application pending·0 cites
- 2554US11607423B2Combination of a cannabinoid and a chemotheraopeutic agent for the treatment of breast cancerAKOS BIOSCIENCES INC·Filed 2019·Granted Mar 21, 2023·0 cites·17 claims
- 2654US6972128B1Use of human prostrate cell lines in prostate cancer treatmentONYVAX LTD·Filed 1999·Granted Dec 6, 2005·13 cites·4 claims
- 2754US2018207263A1Treatment of cancer with naltrexoneCANCER VACCINE INST·Filed 2018·Application pending·0 cites
- 2854US2012164099A1Use of human prostate cell lines in cancer treatmentDALGLEISH ANGUS GEORGE·Filed 2011·Application pending·0 cites
- 2952US2013230600A1Therapeutic agentAIMSCO LTD·Filed 2013·Application pending·0 cites
- 3049US2016136127A1Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumourGW PHARMA LTD·Filed 2014·Application pending·0 cites
- 3149US2012100156A1Therapeutic AgentDALGLEISH ANGUS G·Filed 2011·Application pending·0 cites
- 3248US2022143010A1Cancer treatment comprising naltrexone and a cannabinoidLDN PHARMA LTD·Filed 2020·Application pending·0 cites
- 3346US2010291102A1Therapeutic AgentICE BIOLOG LTD·Filed 2002·Application pending·0 cites
- 3445US9200065B2Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domainGRØNVOLD MAJA SOMMERFELT·Filed 2010·Granted Dec 1, 2015·0 cites·9 claims
- 3545US2016002320A1Therapeutic agentAIMSCO LTD·Filed 2015·Application pending·0 cites
- 3645US2015283124A1Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor CellsCELGENE CORP·Filed 2014·Application pending·0 cites
- 3744US2020101066A1Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancerLDN PHARMA LTD·Filed 2018·Application pending·0 cites
- 3844US2013195890A1Treatment of ms with goat serumAIMSCO LTD·Filed 2013·Application pending·0 cites
- 3943US10251949B2Stabilized HIV-1 peptide constructs comprising the gp120 C5 domain and gp41 hydrophilic domainBIONOR IMMUNO AS·Filed 2015·Granted Apr 9, 2019·0 cites·11 claims
- 4042US2011086046A1Treatment of MS with goat serumHEENEY JONATHAN·Filed 2003·Application pending·0 cites
- 4142US2012190110A1Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapyBARTLETT JUSTIN B·Filed 2012·Application pending·0 cites
- 4240US9226913B2Methods of treating cancer using a combination of an immunomodulatory compound and an artemisinin or a derivative thereofDALGLEISH ANGUS·Filed 2011·Granted Jan 5, 2016·0 cites·7 claims
- 4340US2021299187A1Cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 4432US2022362168A1Administration regimes of cannabinoids in combination with chemotherapeutics against cancerJAY PHARMA INC·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →